Journal
LEUKEMIA & LYMPHOMA
Volume 62, Issue 13, Pages 3138-3146Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/10428194.2021.1953014
Keywords
Indolent; non-Hodgkin's lymphoma; bendamustine; CHOP; late-onset infections
Categories
Ask authors/readers for more resources
Bendamustine may lead to a higher rate of prolonged lymphocytopenia and late-onset neutropenia in patients with indolent non-Hodgkin's lymphoma, compared to other chemotherapy regimens. The incidence of late-onset infections did not differ significantly between bendamustine-based regimens and CHOP/CVP.
Bendamustine is a preferred first-line chemoimmunotherapy regimen for indolent non-Hodgkin's lymphoma (iNHL). Emerging evidence suggests an increased incidence of late-onset complications with bendamustine-based regimens compared with CHOP/CVP; however, this evidence is limited. We retrospectively compared late-onset complications from January 2005 to May 2020 in adults with previously untreated iNHL who received rituximab or obinutuzumab with CHOP, CVP, or bendamustine. Forty-six patients received CHOP/CVP; 119 received bendamustine. No difference in incidence of late-onset infections was observed. Bendamustine led to a higher rate of prolonged and unresolved lymphocytopenia and a greater incidence of late-onset neutropenia. Many patients receiving bendamustine did not have lymphocyte recovery even three years following administration. Ongoing infection prophylaxis with bendamustine-based regimens may offset translation of these laboratory findings to late-onset infectious risk.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available